Albumin Market By Product Type (Human Serum Albumin (HSA), Recombinant Albumin, Bovine Serum Albumin (BSA)), Application (Therapeutics, Drug Formulation and Delivery, Vaccines, Component of Media), & Region for 2025-2035
Published Date: January - 2025 | Publisher: MIR | No of Pages: 320 | Industry: latest updates trending Report | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationAlbumin Market By Product Type (Human Serum Albumin (HSA), Recombinant Albumin, Bovine Serum Albumin (BSA)), Application (Therapeutics, Drug Formulation and Delivery, Vaccines, Component of Media), & Region for 2025-2035
Albumin Market Valuation – 2025-2035
Human Serum Albumin Market size was valued at USD 4,672.89 Million in 2024 and is projected to reach USD 10,405.36 Million by 2035, growing at a CAGR of 7.28% from 2024 to 2035. The albumin market is primarily driven by its widespread use in medical therapy. Albumin is essential for treating a number of disorders including liver disease, shock, burns, and hypoalbuminemia. Albumin infusions aid in the treatment of liver cirrhosis and ascites by maintaining oncotic pressure and managing fluid distribution in the body resulting in better patient outcomes. Similarly, in cases of severe burns or traumatic shock, albumin is used to restore blood volume and speed up recovery highlighting its importance in emergency medicine and intensive care by enabling the
Albumin is in high demand in the global market due to its numerous applications in the medical, pharmaceutical, biotechnological, and veterinary areas. The increasing prevalence of chronic diseases, advances in medical therapies, and the broadening field of biotechnological research highlight albumin’s importance in modern healthcare. Technological advancements, economic expansion in new regions, and the shift to individualized therapy all increase demand for albumin. As the market evolves, addressing ethical and environmental concerns will be critical to maintaining growth and meeting the different requirements of a global population by enabling the market to grow at a CAGR of 7.27% from 2024 to 2035
To Get Detailed Analysis Click here
Albumin MarketDefinition/ Overview
Albumin is a key protein in the human body that is mostly produced by the liver and plays an important role in sustaining many physiological activities. It is the most abundant protein in human plasma contributing for over 60% of all plasma protein. Albumin is a single-chain, non-glycosylated polypeptide made up of 585 amino acids with a molecular weight of about 66.5 kDa. This protein is distinguished by its water solubility and ability to bind to a variety of endogenous and exogenous compounds including hormones, fatty acids, bilirubin, and medicines facilitating their transit through the bloodstream.
The principal medical application of albumin is the treatment of hypoalbuminemia, a marked by low amounts of albumin in the blood. Malnutrition, burns, sepsis, kidney illness, and liver disease can all cause hypoalbuminemia. In such instances, albumin administration aids in the restoration of normal oncotic pressure preventing edema while preserving blood volume and pressure. This is especially crucial in critical care units where patients are at danger of fluid imbalance and shock. Albumin infusions are frequently used in intensive care units (ICUs) to help patients with severe burns, trauma, or septic shock.
The most promising future applications for albumin are as a medication delivery mechanism. Albumin’s natural abundance, biocompatibility, and ability to bind to a variety of molecules make it an ideal vehicle for targeted medication administration. The protein can be designed to deliver therapeutic molecules directly to sick areas increasing therapy efficacy while reducing side effects. Nanotechnology is playing an important role here with albumin-based nanoparticles being produced to transport anticancer medicines, antibiotics, and anti-inflammatory compounds.
GET YOUR FREE SAMPLE REPORT TODAY
What's inside a
industry report?
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
Will the Increasing Prevalence of Hypoalbuminemia and Other Medical Conditions Drive the Albumin Market?
The global need for plasma-derived medicines particularly albumin has increased significantly. This increase is mostly due to an increase in the prevalence of numerous life-threatening ailments, special liver diseases, infections, and the frequency of cardiac procedures all of which can result in hypoalbuminemia. Hypoalbuminemia is a medical disorder defined by low levels of albumin in the blood due to either decreased albumin production or excessive loss via the kidneys, gastrointestinal (GI) tract, skin, or extravascular space. This syndrome is most common in critically ill and hospitalized patients making it a dominant ailment in these populations.
Hypoalbuminemia is common in patients with chronic kidney disease (CKD) and nephrotic syndrome. In certain situations, the kidneys lose their ability to retain albumin resulting in increased excretion in the urine. The resulting low albumin levels in the blood cause edema, malnutrition, and an increased risk of infection. Albumin therapy can assist these patients avoid problems by refilling serum albumin levels, increasing nutritional status, and improving overall quality of life.
The increased prevalence of life-threatening ailments including liver diseases, infections, and cardiac operations that cause hypoalbuminemia is driving the significant increase in demand for plasma-derived therapeutics particularly albumin. Hypoalbuminemia, characterized by decreased albumin production or increased albumin loss is common among critically ill and hospitalized patients. Albumin’s critical role in maintaining oncotic pressure, transferring chemicals, and promoting overall health emphasizes its importance in medicinal therapies. The growing need for albumin-based therapeutics to treat liver illnesses, infections, surgical consequences, and chronic problems such as CKD and gastrointestinal disorders demonstrates the broad range of albumin’s therapeutic applications.
Will Stringent Government Regulations in Several Countries to Limit Product Adoption Hamper the Albumin Market?
Despite its promising applications in medicine and therapies, the albumin market confronts substantial barriers to mainstream adoption. Among these issues include a scarcity of available therapeutic items and rigorous government requirements. These constraints generate significant entry hurdles and impede the development, approval, and distribution of albumin-based products.
The scarcity of therapeutic items is a big challenge. While albumin is adaptable and has shown significant promise in a variety of medical sectors such as medication administration, regenerative medicine, and diagnostics, the market still lacks a wide range of licensed therapeutic albumin products. Creating new albumin-based medicines requires intensive research and a significant financial investment. The hefty expenses of clinical trials along with the complexities of ensuring that albumin products fulfill stringent safety and efficacy standards dissuade many pharmaceutical companies from pursuing substantial research portfolios.
The albumin industry holds great promise for a variety of medical applications but its expansion is hampered by a scarcity of therapeutic goods and severe regulatory requirements. Addressing these issues requires a multidimensional approach that includes regulatory reform, technological innovation, and collaboration across the healthcare ecosystem. By overcoming these obstacles, we will be able to realize the full potential of albumin and provide novel, life-saving therapies to patients all around the world.
Category-Wise Acumens
Will the Higher Sales of Drugs for Treating Hypoalbuminemia Drive the Product Type Segment?
The human serum albumin segment is appearing as the leading force owing to a number of critical variables that demonstrate its market leadership. This in-depth examination investigates the causes behind this dominance and its implications for future market movements. Human serum albumin, a protein generated from human plasma is used in a variety of medicinal applications including volume expansion in critical care, hypoalbuminemia therapy, and medication delivery. Its market domination is mostly due to regulatory approvals, the introduction of new medications, and higher sales of drugs designed to treat a wide range of illnesses.
Increased sales of medications containing human serum albumin have also contributed significantly to the segment’s dominance. Human serum albumin is widely used in clinical settings due to its therapeutic advantages and known safety profile. The rising prevalence of illnesses requiring albumin-based treatments such as chronic liver disease, renal disorders, and burns has fueled demand for these medications. Furthermore, the increased number of surgeries and trauma cases involving albumin as a volume expander has boosted sales. The growing geriatric population which is more vulnerable to these illnesses has further fueled demand for human serum albumin products.
The human serum albumin segment’s dominance in the albumin market is due to a combination of factors such as regulatory approvals, the introduction of new products, and increased sales of albumin-based pharmaceuticals. Continued research & development initiatives increased healthcare investments, and the rising applications of albumin in many medical disciplines all contribute to the segment’s growth. Despite the obstacles, the human serum albumin market has a bright future with advances in biotechnology and personalized medicine projected to fuel ongoing growth and innovation in the years ahead.
Several major drivers drive the North American Human Serum Albumin (HSA) Market, including the region’s sophisticated healthcare infrastructure, increasing demand for biopharmaceutical goods, and emerging technological advancements. North America, particularly the United States, is a hotbed of drug discovery, clinical research, and therapeutic applications, resulting in growing demand for HSA in drug delivery, tissue engineering, and diagnostics. The growth in chronic disorders, including liver disease and hypoalbuminemia, drives up the demand for HSA-based treatments and therapies. Furthermore, due to safety and consistency issues, there is a rising preference for recombinant HSA over plasma-derived products, driving market expansion. North America’s solid regulatory framework and established medical reimbursement mechanisms guarantee that HSAs are widely used in clinical and industrial settings.
Will the Increasing Demand for Albumin in R&D Activities Drive the Application Segment?
The therapeutics section is expected to have the biggest share during the projection period. Several key factors have contributed to this expansion including an increase in the number of product approvals from national regulatory authorities, increased demand for albumin in research and development (R&D) activities which has resulted in innovative product launches and a surge in the adoption of these products for therapeutic purposes. The increasing number of product approvals by national regulatory authorities is a major element driving the therapeutics segment’s growth.
Another major reason fueling the therapeutics segment’s growth is the increasing need for albumin in R&D activities. Albumin-based research is becoming increasingly popular among research institutes and pharmaceutical businesses as they seek new therapeutic applications and produce fresh products. This spike in R&D activities is resulting in creative product releases which is supporting market growth. Scientists are looking at the use of albumin in regenerative medicine where it can enhance tissue repair and regeneration. Albumin-based hydrogels and scaffolds are being created to help heal chronic wounds, burns, and other traumas by creating a favorable environment for cell development and tissue regeneration.
The therapeutics section of the albumin market is expected to rise significantly owing to a combination of factors such as regulatory approvals, increased R&D activity, innovative product launches, and rising use of albumin-based products for therapeutic applications. Albumin’s unique features combined with advances in biotechnology and nanotechnology are boosting its use in medication delivery, regenerative medicine, biopharmaceuticals, and diagnostics. As research uncovers novel therapeutic potentials, albumin is poised to play a critical role in treating some of the most pressing medical concerns providing hope and better outcomes for patients worldwide. The future of albumin in therapeutics is not only bright but revolutionary ushering in a new era of medical innovation and excellence.
Gain Access into Albumin Market Report Methodology
Country/Region-wise Acumens
Will the Increasing Adoption of Therapeutics Product Drive the Market in the Asia Pacific Region?
The Asia Pacific region is emerging as the main player in the worldwide albumin industry with the greatest market share. This region’s dominance is supported by numerous major elements with China leading the way as the world’s largest market for human albumin. The high demand for albumin products in China is a primary driving force behind this growth which is aided by the expansion of production facilities, significant investments in research and development (R&D), and widespread acceptance of therapeutic goods.
Investment in research and development (R&D) is another important element boosting the albumin market in Asia Pacific. Chinese businesses and academic institutions are actively focused on novel applications of albumin in a variety of therapeutic fields. Significant R&D efforts are being made to explore the possibilities of albumin in drug delivery methods, regenerative medicine, and biopharmaceutical formulations. These initiatives are targeted at creating new and improved albumin-based products that will provide better therapeutic effects and solve unmet medical needs.
The Asia Pacific region’s dominance in the worldwide albumin market is due to a number of factors including strong demand for albumin products in China, the expansion of production units, major investments in R&D, and the widespread use of therapeutic goods. China’s dominant position is bolstered by its vast population, expanding healthcare infrastructure, and government attempts to improve healthcare access and quality. Other significant markets, such as India, Japan, and South Korea contribute to the region’s growth as do supporting regulatory systems, economic prosperity, and stakeholder collaboration.
Will Increase in the Plasma Collection Drive the Region in North America?
North America is emerging as a dominant player in the albumin market with the second-largest market share. This climb is fueled by a combination of factors that highlighted the region’s strong growth trajectory in the industry. A significant contribution to this push is the widespread use of albumin products in research and development (R&D) activities. Albumin has found several applications in a variety of industries including pharmaceuticals, biotechnology, academic institutions, and others serving as a versatile tool in the development of innovative treatments, diagnostics, and biomedical technologies.
The region saw a significant increase in plasma collecting activities which are an important upstream component in the manufacture of albumin. Plasma-derived albumin remained a key component in the development of therapeutic albumin formulations demanding a consistent and reliable supply of plasma inputs. The collaborative efforts of plasma collecting centers together with developments in plasma fractionation technologies secured an adequate and sustainable supply of albumin for both domestic and global consumption. This strategic emphasis on plasma collection infrastructure not only increased the region’s self-sufficiency in albumin production but also established it as a prominent player in the global albumin market.
North America’s rise to become a major player in the albumin market was fueled by a convergence of factors including the high use of albumin products in R&D activities, strong demand in the US market, expanding non-therapeutic applications, increasing product approvals, and an increase in plasma collection activities. These characteristics combined to put the region’s albumin market on a stable growth trajectory highlighting its critical role in influencing the future of albumin-based medicines, diagnostics, and biomedical technologies on a global scale.
Competitive Landscape
The albumin market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.
Some of the prominent players operating in the albumin market include
- Albumin Therapeutics, LLC
- Albumedix A/S
- CSL Behring LLC
- Biotest AG
- SeraCare Life Sciences (LGC)
- HiMedia Laboratories Pvt. Ltd.
- Grifols International, S.A.
- Medxbio Pte Ltd.
- Invitria
- RayBiotech, Inc.
- Takeda Pharmaceutical Company Limited (Shire)
- Octapharma AG
- Sigma-Aldrich Co. (Merck KGaA)
Latest Developments
- In August 2023, Dyadic International, Inc., a biotechnology business, reported positive third-party analytical results for their animal-free recombinant serum albumin.
- In July 2023, Kedrion Biopharma, a multinational biopharmaceutical business that produces plasma-derived therapeutic products, expanded its human serum albumin products in China to treat uncommon disorders.
Report Scope
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period |
2021-2031 |
| Growth Rate |
CAGR of ~7.7% from 2024 to 2031 |
| Base Year for Valuation |
2024 |
| Historical Period |
2021-2023 |
| Forecast Period |
2024-2031 |
| Quantitative Units |
Value in USD Billion |
| Report Coverage |
Historical and Forecast Revenue Forecast, Historical and Forecast Volume, Growth Factors, Trends, Competitive Landscape, Key Players, Segmentation Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Players |
CSL Behring, Grifols, S.A., Octapharma AG, Baxter International, Inc., Kedrion S.p.A., Takeda Pharmaceutical Company Limited, LazuLine Bio, InVitria, Albumin Bioscience, Merck KGaA, Thermo Fisher Scientific, Inc., and Sartorius AG. |
| Customization |
Report customization along with purchase available upon request |
Global Human Serum Albumin Market by Concentration
On the basis of Concentration, the Global Human Serum Albumin Market has been segmented into5% Concentration, 10% Concentration, 20%-25% Concentration, and Others. 5% Concentration accounted for the largest market share of 43.53% in 2023, with a market value of USD 2,021.20 Million and is projected to grow at a CAGR of 6.41% during the forecast period. 10% Concentration was the second-largest market in 2023, valued at USD 1,250.30 Million in 2023; it is projected to grow at a CAGR of 5.80%. However, 20%-25% Concentration is projected to grow at the highest CAGR of 6.96%.
Human serum albumin (HSA) at 5% is an isotonic solution that closely resembles the naturally occurring albumin in human plasma. It is frequently used in medicine, especially for fluid resuscitation and volume expansion. Due to its safety, compatibility with the human body, and capacity to sustain oncotic pressure, it is a popular option in various therapeutic situations.
In patients with hypovolemia brough
ACTIVE
They are established vendors with powerful business strategies. However, they do not have strong service/product/solution portfolios. They generally focus on their geographic reach related to the product/service offered. The companies falling under Active category include Albcura and others.
CUTTING EDGE
Vendors that fall in this category generally receive high scores for most evaluation criteria. These players have established service/product portfolios as well as a powerful market presence. They also devise effective business strategies. The companies falling under cutting-edge category include Baxter International Inc., Grifols, Sartorius AG, and Octapharma AG and others.
EMERGING
They are vendors who have started gaining momentum in the market with their niche product offerings. They do not pursue many strong business strategies compared to other established vendors. They might be new entrants in the market and would require some more time before gaining traction in the market. Companies falling under the emerging category include Albumin Bioscience and others.
INNOVATORS
Innovators are vendors that have demonstrated substantial service innovation compared with their competitors. They have highly focused service portfolios. However, they lack strong growth strategies for their overall businesses. The companies falling under the emerging innovators category include InVitria, Akron Biotech, HiMedia Laboratories, Kedrion, and others.
Winning Imperatives
The winning imperative section provides a tabular representation of the company’s products into its core strength products and opportunity areas related to Human Serum Albumin Market. It further includes the Current Focus and Strategy and Threat from Competition. The Current Focus and Strategy are determined with respect to research & developments, innovative designs, technology upgradation, mergers & acquisitions, etc. happened in industry recently. The threat is determined by analyzing the competitor’s present with respect to its newly developed product or solution and also existing solutions.
Current Focus & Strategies
Baxter International Inc. works collaboratively to find sustainable, innovative, and market-driven solutions to fulfill its customers’ demands. The company uses its resources efficiently as it believes in continuous innovation to remain a leader and a pioneer in every sector by tapping new markets and attracting new customers. It is primarily focused on profitable growth and sustainable value creation. Baxter International Inc. has the opportunity to utilize its R&D capabilities for developing products adhering to international rules and regulations and offer diversified products to its customers.
Threat From Competition
The company faces high competition from Grifols, Sartorius, and Octapharma AG key players operating in the Human Serum Albumin Market. In order to compete in the market, Waterproofing Membrane focuses on innovation, carrying out extensive R&D to develop efficient products.
Research Methodology of Market Research
To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .
Reasons to Purchase this Report
• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support
Customization of the Report
• In case of any please connect with our sales team, who will ensure that your requirements are met.
Pivotal Questions Answered in the Study
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy